What Oto Health does

Oto Health is a London-headquartered digital health company that develops evidence-based mobile applications for tinnitus management. Founded by ex-military physicians with personal experience of tinnitus, the company targets adults experiencing persistent tinnitus through a clinically-validated cognitive behavioral therapy (CBT) program delivered via its consumer app, while serving audiologists and hearing specialists through a separate provider platform (Oto Pro) that enables remote patient monitoring and integrated clinical workflows.

The core product is the Oto mobile application, available on iOS and Android, which delivers a structured 6-module CBT program through daily 10-minute guided audio sessions, complemented by a curated sound library for focus, relaxation, and sleep, in-app Tinnitus Functional Index (TFI) assessments for tracking severity over time, live group education sessions, and 61 evidence-informed articles in the Oto Journal. The provider-facing Oto Pro platform adds a clinician dashboard showing patient TFI scores, session completion, and sleep data, alongside onboarding, certification, and ongoing audiologist support. The technology stack uses Firebase for authentication and analytics (UK/EU), Stripe for US payments, RevenueCat for subscription management, PostHog for product analytics on the provider dashboard, and Sentry for error tracking; the company is also pursuing FDA 510(k) clearance for the patient app under IEC 62304 design controls.

Oto operates a hybrid B2B2C and direct-to-consumer model. In the US, the program is delivered exclusively through a network of 299+ licensed audiology practices that bundle the app with their clinical services and monitor outcomes via Oto Pro; UK/EU consumers access the app directly through Apple App Store and Google Play subscriptions processed by RevenueCat. The company has assembled independent clinical evidence including two university-led randomized controlled trials (a 96-participant Flinders University trial and a 198-participant Cambridge DEFINE trial, the largest RCT of a digital tinnitus therapy to date), holds compliance certifications spanning HIPAA, UK/EU GDPR, CCPA/CPRA, and multiple US state privacy regimes, and is headquartered in London with a US subsidiary (Oto Health Inc.) in Dover, Delaware.

Name

Oto Health

Legal name

Oto Health Ltd

Website

https://joinoto.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Oto Health develops evidence-based CBT mobile applications for tinnitus management, serving tinnitus patients and audiologist practices. Its products include the Oto patient app and Oto Pro provider platform, with 200,000+ program enrollments and 299+ US provider partners.

Ownership category

akta.pro rank

Product category

Digital Therapeutics for Tinnitus

NAICS

Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Non-prescription / OTC Digital Therapeutics (HLACANAC)

Keywords

• Digital tinnitus therapy
• CBT mobile health
• Tinnitus management platform
• Audiology practice software
• Digital therapeutics

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. App Subscription (UK/EU): Self-pay consumers in the UK/EU access locked app content through Oto subscriptions, with payments processed via Apple App Store or Google Play. Subscriptions renew automatically unless cancelled.
2. Provider Licensing (US): US users receive access through participating healthcare providers who license the Oto program. The subscription is not directly available to US consumers; access is bundled with provider services.
3. Oto Pro Practice Program: Audiology practices pay for the Oto Pro program which includes provider certification, clinical workflows, the patient app, and ongoing support. This is a B2B licensing model targeting independent audiology practices.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Oto Health develops and sells a digital therapeutics platform for tinnitus management built on evidence-based Cognitive Behavioral Therapy (CBT). The offering includes the Oto consumer mobile app, which delivers a structured 6-module program through daily 10-minute audio sessions, TFI assessments, a curated sound library, and mindfulness content, and Oto Pro, a clinician dashboard that lets audiology practices monitor patient progress remotely. The product is delivered to US patients through licensed audiologist practices and to UK/EU consumers via direct app store subscriptions.

Product overview

Oto Health offers a two-part product portfolio: (1) Oto, the core mobile app delivering evidence-based CBT for tinnitus through daily audio sessions, guided exercises, sound therapy, and relaxation techniques, used by patients at home between clinical appointments; and (2) Oto Pro, a provider-facing platform for audiology practices that includes a patient management dashboard, clinical workflows, provider certification, and dedicated audiologist support. The patient app connects to the provider dashboard, enabling clinicians to monitor patient progress and adjust treatment plans. The Oto program includes a structured 6-module core program, in-app assessments to track TFI progress over time, live group education sessions, and a curated sound library.

Differentiator

Problem solved

Functional benefit

Brands

• Oto Pro: Provider-facing program for audiology practices that includes the Oto app, provider certification, clinical workflows, and ongoing support for tinnitus care.

Products and services

• Oto (Consumer Tinnitus App) Mobile application for adults with tinnitus that delivers an evidence-based, CBT-based structured 6-module program through daily 10-minute audio sessions. Includes TFI assessments, a curated sound library for sleep and relaxation, mindfulness content, and live group education sessions. In the US, the app is accessed through participating audiologist providers; in the UK/EU, it is available via direct app store subscription.
• Oto Pro (Provider Platform) Provider-facing platform for audiology and hearing specialist practices that includes a clinician dashboard for tracking patient TFI scores, session completion, sleep data, and quality-of-life metrics. Includes provider certification, clinical workflows, implementation support, and dedicated audiologist support for integrating CBT-based tinnitus care into practice.

Quantifiable outcome

• TFI reduction of 9 points vs wait-list control at 6 months (95% CI [2, 16], p = .006)
• +3 more outcomes

Named customers9 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability2 records

Feature7 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Flinders UniversitycoreStrategic or Co-development Partner · 1 January 2025Led a 96-participant randomized controlled trial of Oto against wait-list control over 9 months. Published in Speech, Language and Hearing (2025). Reported statistically significant TFI reduction of 9 points at 6 months (Cohen's d = 0.62), sustained at 9 months. Led by Boaz Mui and team at Flinders University College of Education, Psychology and Social Work and Digital Health Research Centre.
• University of CambridgecoreStrategic or Co-development PartnerLed the DEFINE trial (Digital thErapy For Improved tiNnitus carE Study), a 198-participant randomized non-inferiority RCT comparing Oto to therapist-delivered CBT. Trial protocol published in PLOS ONE (January 2024). Principal Investigator: Matt Smith, Assistant Research Professor. Trial partially funded by Innovate UK with sponsorship from Oto Health Ltd. Design, conduct, and analysis carried out independently by Cambridge team.
• NHScoreStrategic or Co-development PartnerCambridge University Hospitals NHS Foundation Trust served as clinical partner for the DEFINE trial, enabling UK-wide decentralized participant involvement without requiring clinic visits.
• Veterans Hearing FoundationminorStrategic or Co-development PartnerUK partnership providing tinnitus support for veterans. Oto has been used to support veterans with tinnitus, with several founders having military medical backgrounds.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Neuromod Devices: Developer of Lenire, a bimodal neuromodulation device for tinnitus that is FDA-cleared. Most direct competitor in the tinnitus digital/interventional therapy category, validated by regulatory clearance and clinical evidence, and competing for the same audiologist channel.
• AudioCardio: Mobile app delivering sound-therapy-based hearing training for tinnitus and hearing loss. Closely comparable as a consumer-facing digital tinnitus therapy with a similar distribution model through audiologists and direct app subscriptions.
• MindEar: CBT- and mindfulness-based digital tinnitus therapy developed with academic researchers. Highly comparable in methodology (CBT for tinnitus), target user (tinnitus sufferers), and delivery format (mobile app), positioning it as a direct methodology peer.
• Tuned: Digital hearing wellness platform offering tinnitus support, hearing care, and audiology services. Comparable in targeting tinnitus sufferers via digital tools and an audiologist provider network, overlapping with Oto's B2B2C model.

Broad incumbents

• Signia (WS Audiology): Major hearing-aid manufacturer with built-in tinnitus therapy features (Notch Therapy, sound therapy) bundled into devices sold through audiologists. Overlaps with Oto in tinnitus treatment but competes via hardware-bundled programs rather than a stand-alone app.
• ReSound (GN Hearing): Global hearing-aid manufacturer offering a ReSound Tinnitus Relief app alongside its device portfolio. Directly overlaps in the audiology channel and in app-based tinnitus management, but Oto's positioning as a clinically-validated digital therapeutic distinguishes it.
• Widex (WS Audiology): Hearing-aid manufacturer with a dedicated WIDEX TINNITUS feature set and sound therapy tools. Competes for audiologist mindshare and is a potential channel alternative for practices evaluating tinnitus offerings.
• Oticon (Demant): Global hearing-aid manufacturer offering Tinnitus SoundSupport and related audiology tools. A broad incumbent whose devices compete with Oto's app for the same clinician recommendation and patient engagement.
• Akili Interactive: Digital therapeutics company (FDA-cleared EndeavorRx for ADHD) operating a similar regulated SaMD business model. Comparable as a public peer in the DTx category for clinical evidence generation, regulatory clearance, and provider/payer commercialization.
• Big Health: Digital therapeutics company focused on insomnia and anxiety (Sleepio, Daylight) using CBT methodology. Closely comparable in business model (prescription digital therapeutic, payer/provider channel, CBT-based interventions), but operates in adjacent conditions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCEPVkVrzS2L7yGvLGgNMWYA
• Xx.com/Join_Oto
• Facebookfacebook.com/ototinnitus

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oto Health